National LAT translational strategy

HALo is advocating for a national strategy that facilitates the economic and healthcare potential of long-acting therapeutics (LAT) within the UK.

A manufacturing strategy for the UK would reduce development risk, accelerate product readiness, and support the delivery of safe, effective, and accessible long-acting therapeutics to market and patients.

To facilitate this, two dedicated platforms will be utilised – the Industrial Forum and the CDMO (Contract Development and Manufacturing Organisation) Forum. They will aim to connect stakeholders, share expertise and accelerate the development of transformative long-acting therapeutics.

The Industrial Forum

Brings together representatives from pharmaceutical companies (start-ups to multinationals), formulation ingredient manufacturers, and technology providers. It offers a space to explore new opportunities, identify industry challenges, and highlight advances in regulatory approaches. Regular meetings and communications will ensure that promising innovations can transition efficiently to market and the clinic.

The CDMO Forum

Focuses on the practical realities of manufacturing long-acting therapeutics at scale. It engages experts in process development, scale-up, quality control, and supply chain logistics to address technical and operational hurdles. The forum enables participants to discuss manufacturing innovations, regulatory compliance requirements, and ways to optimise production timelines without compromising quality.